ArticleCancer management and research2026

LRRC32 Mediates Resistance to Everolimus in Hormone Receptor-Positive, HER2-Negative Breast Cancer.

Liguang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.